Edition:
India

Quest Diagnostics Inc (DGX.N)

DGX.N on New York Stock Exchange

98.90USD
11:10pm IST
Change (% chg)

$-0.09 (-0.09%)
Prev Close
$98.99
Open
$99.39
Day's High
$99.49
Day's Low
$98.66
Volume
57,765
Avg. Vol
330,518
52-wk High
$112.83
52-wk Low
$90.14

Select another date:

Tue, Dec 12 2017

BRIEF-Fresenius Medical Care Closes Divestment Of Shiel Medical Laboratory To Quest Diagnostics

* DGAP-NEWS: FRESENIUS MEDICAL CARE CLOSES DIVESTMENT OF SHIEL MEDICAL LABORATORY TO QUEST DIAGNOSTICS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Quest Diagnostics provides update on impact of 2018 Medicare payment rates

* Quest Diagnostics provides update on impact of final 2018 Medicare payment rates for clinical laboratory tests

BRIEF-FDA approves Clinical Genomics, Quest Diagnostics Insure One

* Clinical Genomics and Quest Diagnostics announce FDA 510(k) clearance of Insure® One™

BRIEF-Quest Diagnostics acquires certain assets of California Laboratory Associates

* Quest Diagnostics acquires California Laboratory Associates

BRIEF-Advantage Capital Portfolio company Cleveland Heartlab acquired by Quest Diagnostics

* Advantage Capital Portfolio company Cleveland Heartlab, Inc acquired by Quest Diagnostics

BRIEF-Quest Diagnostics reports Q3 diluted eps of $1.15

* Quest Diagnostics reports third quarter 2017 financial results, updates 2017 financial guidance and reaffirms long term outlook

BRIEF-Fresenius Medical Care says divests Shiel Medical Laboratory to Quest Diagnostics

* Deal to generate modest book gain for Fresenius Medical Care

BRIEF-Quest Diagnostics provides update on impact to 3rd quarter financial results from hurricanes

* Quest Diagnostics provides update on impact to third quarter financial results from hurricanes

Fitch Affirms Quest Diagnostics at 'BBB'; Outlook Stable

(The following statement was released by the rating agency) NEW YORK, September 27 (Fitch) Fitch Ratings has affirmed the ratings of Quest Diagnostics Incorporated (NYSE: DGX) including the Issuer Default Rating (IDR) at 'BBB'. The Rating Outlook is Stable. A full list of ratings can be found at the end of the release. KEY RATING DRIVERS Leading Market Position: Quest is the largest independent player as measured by segment revenues in the relatively fragmented and highly competitive U.S. clinic

Quest to offer cholesterol testing without fasting requirement

Quest Diagnostics Inc said on Thursday it will begin using a more precise method of calculating levels of "bad" LDL cholesterol that no longer requires fasting prior to blood draw, a development likely to delight patients who previously had to refrain from eating for up to 12 hours before testing.

Select another date: